La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

TC Biopharm (Holdings) Bilan de santé

Santé financière contrôle des critères 5/6

TC Biopharm (Holdings) possède un total de capitaux propres de £1.1M et une dette totale de £0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont £7.3M et de £6.2M.

Informations clés

Ratio d'endettement

UK£0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	UK£980.96k
Fonds propres	UK£1.08m
Total du passif	UK£6.18m
Total des actifs	UK£7.26m

Mises à jour récentes de la santé financière

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de T0U0 ( £4.2M ) ne couvrent pas ses passifs à court terme ( £4.8M ).

Passif à long terme: Les actifs à court terme de T0U0 ( £4.2M ) dépassent ses passifs à long terme ( £1.4M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: T0U0 est sans dette.

Réduire la dette: T0U0 n'avait aucune dette il y a 5 ans.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: T0U0 dispose d'une piste de trésorerie suffisante pour 1 mois sur la base du dernier flux de trésorerie disponible, mais a depuis levé des capitaux supplémentaires.

Prévisions de trésorerie: T0U0 devrait disposer d'une marge de trésorerie suffisante pour 1 mois sur la base des estimations de flux de trésorerie disponible, mais a depuis levé des capitaux supplémentaires.

TC Biopharm (Holdings) Bilan de santé

Santé financière contrôle des critères 5/6

Informations clés

Mises à jour récentes de la santé financière

TC Biopharm (Holdings) Provides Non-Compliance Update

TC Biopharm (Holdings) Regains Compliance with the Nasdaq Stock Market Listing Rule 5550(b)

TC Biopharm Receives Notice of Non-compliance with NASDAQ's Listing Rule 5550(b)(1)

Recent updates

TC Biopharm (Holdings) Plc Announces Dosing of 5 New Patients in ACHIEVE

TC BioPharm (Holdings) PLC Announces Grant of European Patent Covering Use of Modified Gamma Delta Cells for the Treatment of Cancer and Viral Indications

TC Biopharm (Holdings) Plc has filed a Follow-on Equity Offering.

TC Biopharm (Holdings) Plc has completed a Follow-on Equity Offering in the amount of $2 million.

TC BioPharm (Holdings) PLC Announces Dosing of 6th Patient in ACHIEVE Study in Patients with Acute Myeloid Leukemia

TC Biopharm (Holdings) Plc has filed a Follow-on Equity Offering.

TC Biopharm (Holdings) Provides Non-Compliance Update

TC Biopharm (Holdings) Plc Announces Launch of Compassionate Use Program for TCB008

TC Biopharm (Holdings) Plc, Annual General Meeting, Mar 14, 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

TC Biopharm (Holdings) Plc has filed a Follow-on Equity Offering in the amount of $3.5 million.

TC BioPharm (Holdings) PLC Appoints Lauren Bor as Head of Commercial Development Division

High number of new and inexperienced directors

TC Biopharm (Holdings) Plc Announces FDA Clearance of Phase 1B IND for TCB-008 in Acute Myeloid Leukemia

TC Biopharm (Holdings) Plc Announces FDA Clearance of Phase 1B IND for TCB-008 in Acute Myeloid Leukemia

TC Biopharm (Holdings) Regains Compliance with the Nasdaq Stock Market Listing Rule 5550(b)

TC Biopharm (Holdings) Plc, Annual General Meeting, Jun 29, 2023

Full year 2022 earnings released: UK£2.02 loss per share (vs UK£6.49 loss in FY 2021)

High number of new and inexperienced directors

TC Biopharm Appoints Arlene Morris as New Chair of the Board

TC Biopharm (Holdings) Plc Announces Successful Dosing of Final Patient in ACHIEVE Safety Cohort

TC BioPharm (Holdings) plc Announces the Appointment of Bree Harlin as Chief Clinical Officer

TC Biopharm Receives Notice of Non-compliance with NASDAQ's Listing Rule 5550(b)(1)

High number of new and inexperienced directors

TC Biopharm (Holdings) Plc announced that it has received $7.35 million in funding

TC Biopharm (Holdings) Plc announced that it expects to receive $7.35 million in funding

Tc BioPharm Begins Dosing Phase 2B Clinical Study Evaluating Its Lead Compound, Omnimmune(R), in Patients with Acute Myeloid Leukemia

High number of new and inexperienced directors

TC Biopharm (Holdings) Plc, Annual General Meeting, Nov 14, 2022

TC Biopharm (Holdings) Plc Announces Additions to Scientific Advisory Board

TC Biopharm (Holdings) Plc, Annual General Meeting, Nov 01, 2022

TC Biopharm (Holdings) PLC Receives MHRA Approval for 18-Month Extrapolated Shelf-Life of Allogeneic Cell Therapy Product, OmnImmune

High number of new and inexperienced directors

TC Biopharm (Holdings) Plc has completed a Follow-on Equity Offering in the amount of $4 million.

TC Biopharm Announces Formation of Scientific Advisory Board

TC Biopharm (Holdings) Plc Receives CryoTC Trademark for Proprietary Cell Freezing Process

High number of new directors

TC Biopharm (Holdings) Plc Announces Positive Phase 1b/2a Data in Late-Stage Acute Myeloid Leukemia Patients Treated with Allogeneic Gamma Delta T Cells

Insufficient new directors

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines